Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer

被引:7
作者
Hashimoto, Tadayoshi [1 ,2 ,3 ]
Nakayama, Izuma [4 ]
Ohashi, Manabu [5 ]
Mizusawa, Junki [1 ]
Kawachi, Hiroshi [6 ]
Kita, Ryosuke [1 ]
Fukuda, Haruhiko [1 ]
Kurokawa, Yukinori [7 ]
Boku, Narikazu [8 ]
Yoshikawa, Takaki [9 ]
Terashima, Masanori [10 ]
机构
[1] Natl Canc Ctr, Japan Clin Oncol Grp Data Ctr, Operat Off, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Translat Res Support Sect, Kashiwa, Japan
[3] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan
[4] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Koto, Japan
[5] Canc Inst Ariak Hosp, Dept Gastroenterol Surg, Tokyo, Japan
[6] Canc Inst Hosp Japanese Fdn Canc Res, Dept Pathol, Tokyo, Japan
[7] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Osaka, Japan
[8] Univ Tokyo, IMSUT Hosp, Inst Med Sci, Dept Oncol & Gen Med, Tokyo, Japan
[9] Natl Canc Ctr, Dept Gastr Surg, Tokyo, Japan
[10] Shizuoka Canc Ctr, Div Gastr Surg, Nagaizumi 4118777, Japan
关键词
DOS; FLOT; gastric cancer; large type 3; linitis plastica; neoadjuvant chemotherapy; scirrhous; type; 4; CHEMOTHERAPY; SURVIVAL; TUMORS; S-1;
D O I
10.2217/fon-2023-0605
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Macroscopic type 4 and large type 3 gastric cancer, mostly overlapping with scirrhous or linitis plastica type, exhibit a highly invasive nature and show unfavorable prognosis after curative surgery, even with adjuvant chemotherapy. A randomized phase III trial (JCOG0501) failed to demonstrate a survival advantage of neoadjuvant chemotherapy with S-1 plus cisplatin for this population. The current authors initiated a randomized phase II study comparing neoadjuvant chemotherapy with 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for type 4 and large type 3 gastric cancer. 76 patients are planned to be enrolled over two years. The primary end point is the proportion of patients with a pathological response (grade 1b or higher) and secondary end points include overall survival and adverse events.
引用
收藏
页码:2147 / 2155
页数:9
相关论文
共 29 条
  • [1] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Al-Batran, Salah-Eddin
    Homann, Nils
    Pauligk, Claudia
    Goetze, Thorsten O.
    Meiler, Johannes
    Kasper, Stefan
    Kopp, Hans-Georg
    Mayer, Frank
    Haag, Georg Martin
    Luley, Kim
    Lindig, Udo
    Schmiegel, Wolff
    Pohl, Michael
    Stoehlmacher, Jan
    Folprecht, Gunnar
    Probst, Stephan
    Prasnikar, Nicole
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Trojan, Joerg
    Koenigsmann, Michael
    Martens, Uwe M.
    Thuss-Patience, Peter
    Egger, Matthias
    Block, Andreas
    Heinemann, Volker
    Illerhaus, Gerald
    Moehler, Markus
    Schenk, Michael
    Kullmann, Frank
    Behringer, Dirk M.
    Heike, Michael
    Pink, Daniel
    Teschendorf, Christian
    Loehr, Carmen
    Bernhard, Helga
    Schuch, Gunter
    Rethwisch, Volker
    von Weikersthal, Ludwig Fischer
    Hartmann, Joerg T.
    Kneba, Michael
    Daum, Severin
    Schulmann, Karsten
    Weniger, Joerg
    Belle, Sebastian
    Gaiser, Timo
    Oduncu, Fuat S.
    Guentner, Martina
    Hozaeel, Wael
    Reichart, Alexander
    [J]. LANCET, 2019, 393 (10184) : 1948 - 1957
  • [2] Borrmann type IV: An independent prognostic factor for survival in gastric cancer
    An, Ji Yeong
    Kang, Tae Ho
    Choi, Min Gew
    Noh, Jae Hyung
    Sohn, Tae Sung
    Kim, Sung
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (08) : 1364 - 1369
  • [3] [Anonymous], 2017, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
  • [4] KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Ilson, David H.
    Hyung, Woo Jin
    Strong, Vivian E.
    Goetze, Thorsten Oliver
    Yoshikawa, Takaki
    Tang, Laura H.
    Hwang, Peggy May Tan
    Webb, Nancy
    Adelberg, David
    Shitara, Kohei
    [J]. FUTURE ONCOLOGY, 2019, 15 (09) : 943 - 952
  • [5] Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas A Summary of 480 Cases
    Becker, Karen
    Langer, Rupert
    Reim, Daniel
    Novotny, Alexander
    zum Buschenfelde, Christian Meyer
    Engel, Jutta
    Friess, Helmut
    Hofler, Heinz
    [J]. ANNALS OF SURGERY, 2011, 253 (05) : 934 - 939
  • [6] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    Cunningham, David
    Allum, William H.
    Stenning, Sally P.
    Thompson, Jeremy N.
    Van de Velde, Cornelis J. H.
    Nicolson, Marianne
    Scarffe, J. Howard
    Lofts, Fiona J.
    Falk, Stephen J.
    Iveson, Timothy J.
    Smith, David B.
    Langley, Ruth E.
    Verma, Monica
    Weeden, Simon
    Chua, Yu Jo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) : 11 - 20
  • [7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [8] Borrmann Type Predicts Response to Preoperative Therapy in Advanced Gastric Cancer
    Hirata, Yuki
    Agnes, Annamaria
    Prakash, Laura R.
    Mansfield, Paul
    Badgwell, Brian D.
    Ikoma, Naruhiko
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (03) : 882 - 889
  • [9] Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial
    Iwasaki, Yoshiaki
    Terashima, Masanori
    Mizusawa, Junki
    Katayama, Hiroshi
    Nakamura, Kenichi
    Katai, Hitoshi
    Yoshikawa, Takaki
    Ito, Seiji
    Kaji, Masahide
    Kimura, Yutaka
    Hirao, Motohiro
    Yamada, Makoto
    Kurita, Akira
    Takagi, Masakazu
    Lee, Sang-Woong
    Takagane, Akinori
    Yabusaki, Hiroshi
    Hihara, Jun
    Boku, Narikazu
    Sano, Takeshi
    Sasako, Mitsuru
    [J]. GASTRIC CANCER, 2021, 24 (02) : 492 - 502
  • [10] Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)
    Iwasaki, Yoshiaki
    Sasako, Mitsuru
    Yamamoto, Seiichiro
    Nakamura, Kenichi
    Sano, Takeshi
    Katai, Hitoshi
    Tsujinaka, Toshimasa
    Nashimoto, Atsushi
    Fukushima, Norimasa
    Tsuburaya, Akira
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (07) : 741 - 745